Precigen (NASDAQ:PGEN) Sets New 52-Week High – Should You Buy?

Precigen, Inc. (NASDAQ:PGEN) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $5.47 and last traded at $5.4130, with a volume of 353339 shares trading hands. The stock had previously closed at $5.38.

Wall Street Analyst Weigh In

Several research firms recently commented on PGEN. Wall Street Zen lowered shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. HC Wainwright increased their target price on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $12.50.

Precigen Price Performance

The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The stock has a market capitalization of $1.92 billion, a PE ratio of -4.63 and a beta of 1.06. The stock’s 50 day moving average is $4.21 and its two-hundred day moving average is $4.13.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. The company had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. On average, equities analysts anticipate that Precigen, Inc. will post -0.02 EPS for the current fiscal year.

Insider Activity

In other Precigen news, CEO Helen Sabzevari sold 119,250 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $519,930.00. Following the transaction, the chief executive officer owned 3,768,872 shares in the company, valued at approximately $16,432,281.92. This trade represents a 3.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Donald P. Lehr sold 29,131 shares of Precigen stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $127,011.16. Following the sale, the insider directly owned 755,461 shares in the company, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,005,749 shares of company stock valued at $16,765,918 in the last three months. Company insiders own 41.40% of the company’s stock.

Hedge Funds Weigh In On Precigen

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Lansing Street Advisors acquired a new position in shares of Precigen during the 3rd quarter worth approximately $1,800,000. Boxer Capital Management LLC acquired a new stake in shares of Precigen in the third quarter valued at approximately $2,796,000. Occam Crest Management LP lifted its position in Precigen by 29.6% during the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock worth $14,637,000 after buying an additional 799,339 shares in the last quarter. Investment Insight Wealth Management LLC purchased a new position in Precigen during the fourth quarter worth approximately $443,000. Finally, UBS Group AG boosted its stake in Precigen by 41.4% during the fourth quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock worth $3,726,000 after buying an additional 260,824 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.